Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.
Gastrointestinal and vaginal mucosa are major sites of entry in natural HIV infection and therefore the preferred sites to elicit high-avidity CD8+ CTL by vaccination. We directly compare systemic and mucosal immunization in mice after DNA priming and boosting with rgp160 env expressed either in MVA or Ad for their ability to induce mucosal as well as systemic HIV-specific CTL. The optimal CTL response in the gut mucosa was observed after priming with the HIV-1 gp160 env DNA vaccine and boosting with rMVA or rAd encoding the same envelope gene all administered intrarectally (IR). Maximum levels of high-avidity CD8+ T cells were seen in intestinal lamina propria following this regimen. When the prime and boost routes were distinct, the delivery site of the boost had a greater impact than the DNA priming. IM DNA prime and IR rMVA boost were more effective than IR DNA prime and IM rMVA boost for eliciting mucosal CD8+ T-cell avidity. A systemic DNA-prime-followed by systemic rMVA boost induced high levels of high-avidity CD8+ T cells systemically, but responses were undetectable in mucosal sites. A single systemic immunization with rMVA was sufficient to induce high-avidity IFN-gamma secreting CD8+ T cells in systemic organs, whereas a single mucosal immunization with rMVA was not sufficient to elicit high-avidity CD8+ T cells in mucosa. Thus, a heterologous mucosal DNA prime-viral vectored boost strategy was needed. The requirement for a heterologous DNA prime-recombinant viral boost strategy for generation of high-avidity CD8+ T cells in mucosal sites in mice may be more stringent than for the induction of high-avidity CD8+ T cells in systemic compartments.
Belyakov
Igor M
IM
Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA; Midwest Research Institute, Frederick, MD 21702, USA. igorbelyakov@yahoo.com
Ahlers
Jeffrey D
JD
Nabel
Gary J
GJ
Moss
Bernard
B
Berzofsky
Jay A
JA
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D003602:Cytotoxicity, Immunologic; D005260:Female; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D007413:Intestinal Mucosa / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology
D016915:AIDS Vaccines; D019444:Vaccines, DNA
Methods Mol Med. 2006;127:171-97
16988455
Science. 2001 Apr 6;292(5514):69-74
11393868
Health Aff (Millwood). 2007 Jul-Aug;26(4):1147-58
17630459
J Virol. 2003 Feb;77(4):2400-9
12551977
J Exp Med. 2000 Jul 3;192(1):63-75
10880527
J Virol. 2004 Jul;78(14):7490-7
15220422
J Immunol. 2006 Nov 1;177(9):6336-43
17056564
J Immunol. 2003 Sep 1;171(5):2538-47
12928404
J Clin Invest. 2001 Dec;108(11):1677-85
11733563
J Virol. 2001 Dec;75(23):11483-95
11689630
J Immunol. 2002 Jan 1;168(1):332-7
11751978
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7
10759543
J Immunol. 2001 Dec 15;167(12):7180-91
11739541
Nature. 2002 Jan 17;415(6869):331-5
11797011
J Immunol. 2000 May 1;164(9):4968-78
10779808
Immunol Rev. 2007 Feb;215:226-42
17291292
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1709-14
9465081
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
8633023
Immunity. 2004 Mar;20(3):247-53
15030769
J Immunol. 2000 Dec 1;165(11):6454-62
11086085
Virology. 2008 Mar 15;372(2):260-72
18048074
Blood. 2006 Apr 15;107(8):3258-64
16373659
Nat Med. 2000 Feb;6(2):200-6
10655110
Nat Med. 2001 Dec;7(12):1320-6
11726972
Int Immunol. 2002 Jan;14(1):31-7
11751749
Infect Immun. 1997 Apr;65(4):1387-94
9119478
J Immunol. 2006 Jul 15;177(2):831-9
16818737
Curr Mol Med. 2003 May;3(3):285-301
12699364
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7
10200293
Science. 1999 Nov 12;286(5443):1353-7
10558989
Immunity. 2004 Oct;21(4):527-38
15485630
J Clin Invest. 1998 Dec 15;102(12):2072-81
9854042
J Clin Invest. 2004 Aug;114(4):450-62
15314679
J Virol. 2003 Jun;77(12):7048-57
12768024
J Med Primatol. 2002 Aug;31(4-5):217-27
12390544
J Virol. 1989 Oct;63(10):4277-84
2778875
Vaccine. 2002 Jan 31;20(9-10):1295-307
11818148
J Exp Med. 2004 Sep 20;200(6):749-59
15365096
Nature. 2005 Apr 28;434(7037):1093-7
15793563
Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9
2452443
J Virol. 2001 May;75(10):4947-51
11312370
J Clin Virol. 2004 Dec;31 Suppl 1:S69-82
15567097
Virology. 2006 Oct 25;354(2):299-315
16904153
J Clin Invest. 2004 Apr;113(7):998-1007
15057306
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S65-73
15285706
J Virol. 2003 Jun;77(11):6305-13
12743287
J Immunol. 2006 May 1;176(9):5338-45
16622001
J Virol. 1998 Dec;72(12):10180-8
9811759
J Virol. 2003 Nov;77(21):11708-17
14557656
Immunol Rev. 1999 Aug;170:151-72
10566149
Vaccine. 1998 Mar;16(5):439-45
9491498
J Immunol. 1999 Jan 15;162(2):989-94
9916724
J Virol. 2002 Jun;76(11):5357-68
11991964
Curr HIV Res. 2003 Jul;1(3):287-94
15046253
J Gene Med. 2003 Jan;5(1):3-10
12516046
Virology. 2007 Oct 10;367(1):156-67
17590405
AIDS. 1998 Dec 24;12(18):2407-15
9875578
Virology. 2003 Aug 15;313(1):13-21
12951017
J Exp Med. 2006 May 15;203(5):1249-58
16636134
Vaccine. 2007 Mar 8;25(12):2187-93
17229501
J Exp Med. 1996 Jan 1;183(1):215-25
8551225
J Immunol. 2000 Feb 1;164(3):1602-11
10640781
J Immunol. 1999 Feb 15;162(4):2227-34
9973498
J Clin Invest. 2004 Jun;113(11):1515-25
15173875
J Immunol. 2007 Sep 15;179(6):3504-14
17785784
J Virol. 2006 Apr;80(8):3732-42
16571790
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63
12869693
Science. 1998 Apr 17;280(5362):427-31
9545219
J Virol. 1998 Oct;72(10):8264-72
9733870
J Exp Med. 1998 May 18;187(10):1647-57
9584143
J Immunol. 2001 Feb 1;166(3):1690-7
11160212
Science. 2002 Jun 28;296(5577):2335
12090274
J Immunol. 2007 Feb 15;178(4):2370-9
17277143
J Exp Med. 2004 Sep 20;200(6):761-70
15365095
J Immunol. 2007 Jun 1;178(11):7211-21
17513770
Int Immunol. 2007 Dec;19(12):1413-20
17981793
Eur J Immunol. 2001 Dec;31(12):3557-66
11745375